Abbott Laboratories Valuation

ABT Stock  USD 118.95  0.99  0.84%   
At this time, the firm appears to be overvalued. Abbott Laboratories shows a prevailing Real Value of $113.96 per share. The current price of the firm is $118.95. Our model approximates the value of Abbott Laboratories from analyzing the firm fundamentals such as return on equity of 0.15, and Profit Margin of 0.14 % as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Abbott Laboratories' valuation include:
Price Book
5.1411
Enterprise Value
211.8 B
Enterprise Value Ebitda
20.0102
Price Sales
4.9639
Forward PE
22.8833
Overvalued
Today
118.95
Please note that Abbott Laboratories' price fluctuation is very steady at this time. Calculation of the real value of Abbott Laboratories is based on 3 months time horizon. Increasing Abbott Laboratories' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Abbott Laboratories' intrinsic value may or may not be the same as its current market price of 118.95, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value.
Historical Market  118.95 Real  113.96 Target  110.65 Hype  119.01 Naive  121.44
The intrinsic value of Abbott Laboratories' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Abbott Laboratories' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
112.86
Downside
113.96
Real Value
130.85
Upside
Estimating the potential upside or downside of Abbott Laboratories helps investors to forecast how Abbott stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Abbott Laboratories more accurately as focusing exclusively on Abbott Laboratories' fundamentals will not take into account other important factors:
Earnings
Estimates (0)
LowProjectedHigh
1.171.171.18
Details
Hype
Prediction
LowEstimatedHigh
117.91119.01120.11
Details
Potential
Annual Dividend
LowForecastedHigh
1.391.411.43
Details
27 Analysts
Consensus
LowTarget PriceHigh
100.69110.65122.82
Details
Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Abbott Laboratories' intrinsic value based on its ongoing forecasts of Abbott Laboratories' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Abbott Laboratories' closest peers.

Abbott Laboratories Cash

3.68 Billion

Abbott Valuation Trend

Abbott Laboratories' real value is important for investors to make better decisions and a more accurate overall view of Abbott Laboratories' financial worth over time. Using both Abbott Laboratories' enterprise value as well as its market capitalization is the best way to gauge the value of the company and is usually enough for investors to make market timing conclusions.

Abbott Revenue by Product

Abbott Laboratories Total Value Analysis

Abbott Laboratories is presently forecasted to have company total value of 211.79 B with market capitalization of 204.6 B, debt of 15.87 B, and cash on hands of 9.88 B. Please note that company total value may be misleading and is a subject to accounting gimmicks. We encourage investors to carefully check all of the Abbott Laboratories fundamentals before making security assessment based on enterprise value of the company
  Takeover PriceMarket CapDebt ObligationsCash
211.79 B
204.6 B
15.87 B
9.88 B

Abbott Laboratories Investor Information

About 78.0% of the company shares are held by institutions such as insurance companies. The company has Price/Earnings To Growth (PEG) ratio of 2.29. Abbott Laboratories last dividend was issued on the 15th of October 2024. The entity had 10000:4798 split on the 2nd of January 2013. Based on the key indicators related to Abbott Laboratories' liquidity, profitability, solvency, and operating efficiency, Abbott Laboratories may be sliding down financialy. It has an above-average probability of going through some form of financial hardship next quarter.
Current ValueLast YearChange From Last Year 10 Year Trend
Operating Profit Margin0.210.1615
Significantly Up
Pretty Stable
Total Cash From Operating Activities5.2 B7.3 B
Way Down
Slightly volatile
Operating Income3.8 B6.5 B
Way Down
Slightly volatile

Abbott Laboratories Asset Utilization

The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Abbott Laboratories has an asset utilization ratio of 54.78 percent. This implies that the Company is making $0.55 for each dollar of assets. An increasing asset utilization means that Abbott Laboratories is more efficient with each dollar of assets it utilizes for everyday operations.
 
Black Monday
 
Oil Shock
 
Dot-com Bubble
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid

Abbott Laboratories Ownership Allocation

Abbott Laboratories holds a total of 1.73 Billion outstanding shares. The majority of Abbott Laboratories outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in Abbott Laboratories to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Abbott Laboratories. Please pay attention to any change in the institutional holdings of Abbott Laboratories as this could imply that something significant has changed or is about to change at the company. Please note that on September 18, 2024, Representative Michael McCaul of US Congress acquired $50k to $100k worth of Abbott Laboratories's common stock.

Abbott Laboratories Profitability Analysis

The company reported the last year's revenue of 40.11 B. Total Income to common stockholders was 5.72 B with profit before taxes, overhead, and interest of 24.58 B.

Abbott Laboratories Past Distributions to stockholders

About Abbott Laboratories Valuation

The stock valuation mechanism determines Abbott Laboratories' current worth on a daily basis. In general, an absolute valuation approach attempts to find the value of Abbott Laboratories based exclusively on its fundamental and basic technical indicators. As compared to an absolute model, our relative valuation model uses a comparative analysis of Abbott Laboratories. We calculate exposure to Abbott Laboratories's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Abbott Laboratories's related companies.
Last ReportedProjected for Next Year
Gross Profit22.1 B12.5 B
Pretax Profit Margin 0.17  0.21 
Operating Profit Margin 0.16  0.21 
Net Profit Margin 0.14  0.15 
Gross Profit Margin 0.55  0.62 

Abbott Laboratories Quarterly Retained Earnings

39.06 Billion

Abbott Laboratories' stock price is the clearest measure of market expectations about its performance. Without stock valuation, investors cannot independently discern whether Abbott Laboratories' value is low or high relative to the company's performance and growth projections. Determining the market value of Abbott Laboratories can be done in different ways, such as multiplying its stock price by its outstanding shares.
A single share of Abbott Laboratories represents a small ownership stake in the entity. As a stockholder of Abbott, your percentage of company ownership is determined by dividing the number of shares you own by the total number of shares outstanding and then multiplying that amount by 100. Owning stock in a company generally confers both corporate voting rights and income from any dividends paid to the stock owner.

Abbott Laboratories Dividends Analysis For Valuation

At this time, Abbott Laboratories' Dividends Paid is comparatively stable compared to the past year. Dividend Paid And Capex Coverage Ratio is likely to gain to 1.90 in 2024, whereas Dividend Yield is likely to drop 0.02 in 2024. . Retained Earnings is likely to gain to about 39.4 B in 2024, whereas Retained Earnings Total Equity is likely to drop slightly above 27.2 B in 2024.
Last ReportedProjected for Next Year
Dividends Paid3.6 B3.7 B
Dividend Yield 0.02  0.02 
Dividend Payout Ratio 0.62  0.49 
Dividend Paid And Capex Coverage Ratio 1.26  1.90 
There are various types of dividends Abbott Laboratories can pay to its shareholders, and the actual value of the dividend is determined on a per-share basis. It is to be paid equally to all of Abbott shareholders on a specific date, known as the payable date. The cash dividend is the most common type of dividend payment - it is the payment of actual cash from Abbott Laboratories directly to its shareholders. There are other types of dividends that companies can issue, such as stock dividends or asset dividends. When Abbott pays a dividend, it has no impact on its enterprise value. It does, however, lowers the Equity Value of Abbott Laboratories by the value of the dividends paid out.

Abbott Laboratories Growth Indicators

Investing in growth stocks can be very risky. If the company such as Abbott Laboratories does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
Common Stock Shares Outstanding1.7 B
Quarterly Earnings Growth Y O Y0.146
Forward Price Earnings22.8833

Abbott Laboratories Current Valuation Indicators

Abbott Laboratories' valuation analysis is a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final Abbott Laboratories' valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Abbott Laboratories, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Abbott Laboratories' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Abbott Laboratories' worth.

Additional Tools for Abbott Stock Analysis

When running Abbott Laboratories' price analysis, check to measure Abbott Laboratories' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Abbott Laboratories is operating at the current time. Most of Abbott Laboratories' value examination focuses on studying past and present price action to predict the probability of Abbott Laboratories' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Abbott Laboratories' price. Additionally, you may evaluate how the addition of Abbott Laboratories to your portfolios can decrease your overall portfolio volatility.